Perspective
Nature Reviews Drug Discovery 5, 723-729 (September 2006) | doi:10.1038/nrd2131
Outlook: Can open-source R&D reinvigorate drug research?
Bernard Munos1 About the author
Top of page
Abstract
The low number of novel therapeutics approved by the US FDA in recent years continues to cause great concern about productivity and declining innovation. Can open-source drug research and development, using principles pioneered by the highly successful open-source software movement, help revive the industry?
Author affiliations
-
Bernard Munos is at Eli Lilly & Co., Lilly Corporate Center, 1085, Indianapolis, Indiana 46285, USA.
Email: bhmunos@stanfordalumni.org
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
The effect of a first kidney transplant on a subsequent transplant outcome: An experimental and clinical studyKidney International Original Article